Black Diamond Therapeutics Inc
BDTX2.830USD
+0.240+9.27%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
160.40MValor de mercado
31.51P/L TTM
Mais detalhes de Black Diamond Therapeutics Inc Empresa
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.
Informações da empresa
Código da empresaBDTX
Nome da EmpresaBlack Diamond Therapeutics Inc
Data de listagemJan 30, 2020
CEODr. Mark A. Velleca, M.D., Ph.D.
Número de funcionários24
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 30
EndereçoOne Main Street, 14th Floor
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Telefone16174175868
Sitehttps://www.blackdiamondtherapeutics.com/
Código da empresaBDTX
Data de listagemJan 30, 2020
CEODr. Mark A. Velleca, M.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
77.15K
+8.69%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-0.03%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
22.52K
+32.52%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Mark A. Velleca, M.D., Ph.D.
Dr. Mark A. Velleca, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
77.15K
+8.69%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-0.03%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
22.52K
+32.52%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 2 de jul
Atualizado em: qua, 2 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
18.29%
Versant Ventures
10.92%
Vestal Point Capital, LP
9.85%
New Enterprise Associates (NEA)
7.82%
Bellevue Asset Management AG
4.81%
Other
48.32%
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
18.29%
Versant Ventures
10.92%
Vestal Point Capital, LP
9.85%
New Enterprise Associates (NEA)
7.82%
Bellevue Asset Management AG
4.81%
Other
48.32%
Tipos de investidores
Investidores
Proporção
Investment Advisor
36.89%
Venture Capital
18.81%
Investment Advisor/Hedge Fund
18.59%
Hedge Fund
7.37%
Research Firm
1.43%
Individual Investor
0.96%
Bank and Trust
0.18%
Pension Fund
0.02%
Other
15.76%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
254
48.67M
85.58%
-26.49M
2025Q1
261
50.38M
88.73%
-26.95M
2024Q4
246
57.08M
100.88%
-16.52M
2024Q3
250
57.38M
101.59%
-12.76M
2024Q2
242
55.35M
99.47%
-3.18M
2024Q1
244
48.01M
92.96%
-13.90M
2023Q4
235
47.28M
91.68%
-8.00M
2023Q3
256
45.71M
88.75%
-9.85M
2023Q2
259
50.33M
103.17%
+16.38M
2023Q1
277
29.49M
80.76%
-7.91M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
T. Rowe Price Investment Management, Inc.
10.40M
18.29%
-67.48K
-0.64%
Mar 31, 2025
Versant Ventures
6.21M
10.92%
-221.60K
-3.45%
Apr 11, 2025
Vestal Point Capital, LP
5.60M
9.85%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
4.45M
7.82%
--
--
Apr 11, 2025
Bellevue Asset Management AG
2.73M
4.81%
-5.78M
-67.91%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.36M
4.15%
-47.11K
-1.96%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
4.14%
-57.11K
-2.37%
Mar 31, 2025
Tang Capital Management, LLC
2.07M
3.64%
--
--
Mar 31, 2025
Millennium Management LLC
1.10M
1.94%
+545.84K
+97.81%
Mar 31, 2025
Invus Public Equities Advisors, LLC
1.05M
1.84%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Fidelity Enhanced Small Cap ETF
0.04%
iShares Micro-Cap ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Health Innovation Active ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Ver Mais
Fidelity Enhanced Small Cap ETF
Proporção0.04%
iShares Micro-Cap ETF
Proporção0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.01%
iShares Russell 2000 Growth ETF
Proporção0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
iShares Health Innovation Active ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
DFA Dimensional US Core Equity Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
